September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Serum cytokine concentrations before and after starting of infliximab therapy
Author Affiliations & Notes
  • Hisae Nakahara
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
    Ophthalmology, JCHO Tokyo Takanawa Hospital, Minato-ku, Tokyo, Japan
  • Toshikatsu Kaburaki
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Rie Tanaka
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Kazuyoshi Ohtomo
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Mitsuko Takamoto
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Ayako Karakawa
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Kimiko Okinaga
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Junko Matsuda
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Yujiro Fujino
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Hidetoshi Kawashima
    Ophthalmology, Jichi Medical University, Tochigi, Japan
  • Makoto Aihara
    Ophthalmology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Hisae Nakahara, None; Toshikatsu Kaburaki, None; Rie Tanaka, None; Kazuyoshi Ohtomo, None; Mitsuko Takamoto, None; Ayako Karakawa, None; Kimiko Okinaga, None; Junko Matsuda, None; Yujiro Fujino, None; Hidetoshi Kawashima, None; Makoto Aihara, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 501. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hisae Nakahara, Toshikatsu Kaburaki, Rie Tanaka, Kazuyoshi Ohtomo, Mitsuko Takamoto, Ayako Karakawa, Kimiko Okinaga, Junko Matsuda, Yujiro Fujino, Hidetoshi Kawashima, Makoto Aihara; Serum cytokine concentrations before and after starting of infliximab therapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):501.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Whereas the correlations between serum cytokine concentrations and activities of ocular Behçet’s disease had been repeatedly investigated, those of the patients during infliximab therapy have not yet been clarified. We examined serum cytokine concentrations before and after the induction of infliximab therapy for ocular Behçet’s disease.

Methods : Fifteen ocular Behçet’s disease patients (12 men : 3 women, 5 complete type : 10 incomplete type, 38.3 ± 2.2 years old), who visited the outpatient clinics of University of Tokyo Hospital and infliximab was induced, and sixteen healthy persons (12 men : 4 women, 45.0 ± 3.5 years old) were enrolled. The serums of ocular Behçet’s disease patients within one year before and after the induction of infliximab therapy as well as healthy persons were collected. Serum concentrations of IL-4, IL-23, IL-12p70, TNF-α, IFN-γ, IL-21, IL-6, IL-17A, IL-10, and IL-27 were examined by Sandwich ELISA method.

Results : Before the induction of infliximab therapy for ocular Behçet’s disease, the serum concentrations of IL-23, TNF-α, IL-21, IL-6, IL-17A, and IL-27 were higher than those of healthy persons (p<0.05). After the induction, the serum concentrations of IL-23, IL-12p70, TNF-α, IL-21, IL-6, IL-17, and IL-27 were higher than those of healthy persons (p<0.05). The serum concentration of IL-17 after the induction was higher than that of before the induction (p<0.01). For the five patients who had ocular attack after the induction, the serum concentration of IL-21 was higher at the phase of ocular attack than those without ocular attack (p<0.05).

Conclusions : There is a probability that infliximab therapy for ocular Behçet’s disease induces the elevation of serum concentration of IL-17. The serum concentration of IL-21 may be increased at the phase of ocular attacks after starting infliximab.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×